肿瘤科

订阅

MedSci主页 / 所有栏目 / 肿瘤科

Cancer Immunol Immunother：卵巢癌免疫治疗方案的新研究探索

2020-07-08 MedSci原创 MedSci原创

卵巢癌
关注

卵巢癌(OC)患者的标准治疗(SOC)一线治疗受到高复发率的困扰。多项研究表明，免疫系统在改变OC患者病程中的突出作用。目前正在探索的化疗免疫治疗方案包括奥瑞戈单抗，这是一种针对OC相关抗原碳水化合物

卵巢癌(OC)患者的标准治疗(SOC)一线治疗受到高复发率的困扰。同时，卵巢癌一般被认为是冷肿瘤，即对肿瘤免疫治疗并不敏感。

多项研究表明，免疫系统在改变OC患者病程中的突出作用。目前正在探索的化疗免疫治疗方案包括奥瑞戈单抗（Oregovomab），这是一种针对OC相关抗原碳水化合物/癌抗原125（CA125）的特异性单克隆抗体，在之前的一项研究中，与SOC一起给药时产生了可喜的结果。

CA125是众所周知的卵巢癌的生物标志物，Oregovomab针对CA125，可能具有治疗卵巢癌的作用。

QPT-ORE-002多中心II期随机对照研究表明，在晚期OC患者中，与单独使用SOC相比，奥雷戈单抗联合一线SOC可改善总生存期和无进展生存期。该研究纳入了一个意大利队列，我们证明在SOC的基础上加入奥雷戈沃单抗会导致CA125特异性CD8+T淋巴细胞/ml外周血数量放大的患者数量增加，这可能是SOC+奥雷戈沃单抗比单用SOC治疗效果改善的原因。

预测奥雷戈沃单抗疗效的是基线时免疫环境抑制性较低，如循环骨髓源性抑制细胞、亚组4型的数量较低，以及中性粒细胞和单核细胞与淋巴细胞的比例较低。

原始出处：

Alessandra Battaglia, Alexia Buzzonetti, et al., Translational Immune Correlates of Indirect Antibody Immunization in a Randomized Phase II Study Using Scheduled Combination Therapy With carboplatin/paclitaxel Plus Oregovomab in Ovarian Cancer Patients. Cancer Immunol Immunother. 2020 Mar;69(3):383-397. doi: 10.1007/s00262-019-02456-z.

版权声明：
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料，版权均属于梅斯医学所有。非经授权，任何媒体、网站或个人不得转载，授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章，或“梅斯号”自媒体发布的文章，仅系出于传递更多信息之目的，本站仅负责审核内容合规，其内容不代表本站立场，本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系，我们将立即进行删除处理。
在此留言
评论区 (4)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1905139, encodeId=61d71905139b4, content=<a href='/topic/show?id=21f66464823' target=_blank style='color:#2F92EE;'>#治疗方案#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=64648, encryptionId=21f66464823, topicName=治疗方案)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5ee4187, createdName=zhangjiqing, createdTime=Sun Feb 07 07:51:37 CST 2021, time=2021-02-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=801787, encodeId=17f6801e874b, content=<a href='/topic/show?id=08f236865a8' target=_blank style='color:#2F92EE;'>#卵巢癌#</a>CA125抗体，算不算免疫治疗？, beContent=null, objectType=article, channel=null, level=null, likeNumber=178, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=36865, encryptionId=08f236865a8, topicName=卵巢癌)], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220519/c2ab253484ee4527a2d4e9589a4821ac/45de9bf494a54becb2ea4369c9d11e85.jpg, createdBy=7a3710, createdName=lovetcm, createdTime=Wed Jul 08 23:29:03 CST 2020, time=2020-07-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=801760, encodeId=c313801e60e2, content=好好学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=85, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/DOvXMcIPUdiaLyok4kPvSK9sexiaPhdJokodY8ia6A4I9S1AwDL052j6KK5pdjb90JwYflDOaIkkPApVQ7TuiaflFA/132, createdBy=eb525328459, createdName=roxx, createdTime=Wed Jul 08 18:39:10 CST 2020, time=2020-07-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=801740, encodeId=c5bf801e4015, content=学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=87, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/NUyjXTCJjo6EF3hKja8nER8RMzxQdria9eCYFhgLTLsDOeqnvIYdeLDz5eP6EnicLuE5gibiawgno4zUA0jAR7Nbtp2llQ9fs3Mk/0, createdBy=278f1986883, createdName=医鸣惊人, createdTime=Wed Jul 08 16:29:02 CST 2020, time=2020-07-08, status=1, ipAttribution=)]
    2021-02-07 zhangjiqing

    #治疗方案#

    0

  2. [GetPortalCommentsPageByObjectIdResponse(id=1905139, encodeId=61d71905139b4, content=<a href='/topic/show?id=21f66464823' target=_blank style='color:#2F92EE;'>#治疗方案#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=64648, encryptionId=21f66464823, topicName=治疗方案)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5ee4187, createdName=zhangjiqing, createdTime=Sun Feb 07 07:51:37 CST 2021, time=2021-02-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=801787, encodeId=17f6801e874b, content=<a href='/topic/show?id=08f236865a8' target=_blank style='color:#2F92EE;'>#卵巢癌#</a>CA125抗体，算不算免疫治疗？, beContent=null, objectType=article, channel=null, level=null, likeNumber=178, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=36865, encryptionId=08f236865a8, topicName=卵巢癌)], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220519/c2ab253484ee4527a2d4e9589a4821ac/45de9bf494a54becb2ea4369c9d11e85.jpg, createdBy=7a3710, createdName=lovetcm, createdTime=Wed Jul 08 23:29:03 CST 2020, time=2020-07-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=801760, encodeId=c313801e60e2, content=好好学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=85, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/DOvXMcIPUdiaLyok4kPvSK9sexiaPhdJokodY8ia6A4I9S1AwDL052j6KK5pdjb90JwYflDOaIkkPApVQ7TuiaflFA/132, createdBy=eb525328459, createdName=roxx, createdTime=Wed Jul 08 18:39:10 CST 2020, time=2020-07-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=801740, encodeId=c5bf801e4015, content=学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=87, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/NUyjXTCJjo6EF3hKja8nER8RMzxQdria9eCYFhgLTLsDOeqnvIYdeLDz5eP6EnicLuE5gibiawgno4zUA0jAR7Nbtp2llQ9fs3Mk/0, createdBy=278f1986883, createdName=医鸣惊人, createdTime=Wed Jul 08 16:29:02 CST 2020, time=2020-07-08, status=1, ipAttribution=)]
    2020-07-08 lovetcm

    #卵巢癌#CA125抗体，算不算免疫治疗？

    0

  3. [GetPortalCommentsPageByObjectIdResponse(id=1905139, encodeId=61d71905139b4, content=<a href='/topic/show?id=21f66464823' target=_blank style='color:#2F92EE;'>#治疗方案#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=64648, encryptionId=21f66464823, topicName=治疗方案)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5ee4187, createdName=zhangjiqing, createdTime=Sun Feb 07 07:51:37 CST 2021, time=2021-02-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=801787, encodeId=17f6801e874b, content=<a href='/topic/show?id=08f236865a8' target=_blank style='color:#2F92EE;'>#卵巢癌#</a>CA125抗体，算不算免疫治疗？, beContent=null, objectType=article, channel=null, level=null, likeNumber=178, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=36865, encryptionId=08f236865a8, topicName=卵巢癌)], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220519/c2ab253484ee4527a2d4e9589a4821ac/45de9bf494a54becb2ea4369c9d11e85.jpg, createdBy=7a3710, createdName=lovetcm, createdTime=Wed Jul 08 23:29:03 CST 2020, time=2020-07-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=801760, encodeId=c313801e60e2, content=好好学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=85, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/DOvXMcIPUdiaLyok4kPvSK9sexiaPhdJokodY8ia6A4I9S1AwDL052j6KK5pdjb90JwYflDOaIkkPApVQ7TuiaflFA/132, createdBy=eb525328459, createdName=roxx, createdTime=Wed Jul 08 18:39:10 CST 2020, time=2020-07-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=801740, encodeId=c5bf801e4015, content=学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=87, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/NUyjXTCJjo6EF3hKja8nER8RMzxQdria9eCYFhgLTLsDOeqnvIYdeLDz5eP6EnicLuE5gibiawgno4zUA0jAR7Nbtp2llQ9fs3Mk/0, createdBy=278f1986883, createdName=医鸣惊人, createdTime=Wed Jul 08 16:29:02 CST 2020, time=2020-07-08, status=1, ipAttribution=)]
    2020-07-08 roxx

    好好学习

    0

  4. [GetPortalCommentsPageByObjectIdResponse(id=1905139, encodeId=61d71905139b4, content=<a href='/topic/show?id=21f66464823' target=_blank style='color:#2F92EE;'>#治疗方案#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=64648, encryptionId=21f66464823, topicName=治疗方案)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5ee4187, createdName=zhangjiqing, createdTime=Sun Feb 07 07:51:37 CST 2021, time=2021-02-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=801787, encodeId=17f6801e874b, content=<a href='/topic/show?id=08f236865a8' target=_blank style='color:#2F92EE;'>#卵巢癌#</a>CA125抗体，算不算免疫治疗？, beContent=null, objectType=article, channel=null, level=null, likeNumber=178, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=36865, encryptionId=08f236865a8, topicName=卵巢癌)], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220519/c2ab253484ee4527a2d4e9589a4821ac/45de9bf494a54becb2ea4369c9d11e85.jpg, createdBy=7a3710, createdName=lovetcm, createdTime=Wed Jul 08 23:29:03 CST 2020, time=2020-07-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=801760, encodeId=c313801e60e2, content=好好学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=85, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/DOvXMcIPUdiaLyok4kPvSK9sexiaPhdJokodY8ia6A4I9S1AwDL052j6KK5pdjb90JwYflDOaIkkPApVQ7TuiaflFA/132, createdBy=eb525328459, createdName=roxx, createdTime=Wed Jul 08 18:39:10 CST 2020, time=2020-07-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=801740, encodeId=c5bf801e4015, content=学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=87, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/NUyjXTCJjo6EF3hKja8nER8RMzxQdria9eCYFhgLTLsDOeqnvIYdeLDz5eP6EnicLuE5gibiawgno4zUA0jAR7Nbtp2llQ9fs3Mk/0, createdBy=278f1986883, createdName=医鸣惊人, createdTime=Wed Jul 08 16:29:02 CST 2020, time=2020-07-08, status=1, ipAttribution=)]
    2020-07-08 医鸣惊人

    学习

    0

相关资讯

Cancer Sci：Pembrolizumab单抗治疗在日本晚期卵巢癌患者中的应用

对376名既往治疗过的晚期复发性卵巢癌（ROC）患者进行的2个队列、2期KEYNOTE-100研究（NCT02674061）的中期结果显示，彭博利珠单抗单药治疗与8.0%的客观反应率（95% CI，5

Lancet Oncology: 阻碍DNA修复的新途径药物与化疗相结合可以抑制卵巢癌

高级别浆液性卵巢癌（HGSOC）是卵巢上皮性癌中最常见的一种，恶性程度较高，容易出现转移，因此大多数患者就诊时已属晚期。当然也有少部分患者由于偶然的因素被早期发现，治愈率接近100%。近日，一项针对H

尹如铁教授：HRD检测扩大复发性卵巢癌后线治疗获益人群，国内产品首次用于PARPi临床试验入组HRD检测

反复复发是卵巢癌的治疗难点，多次复发的患者治疗也会越来越困难，对于复发性的铂敏感和铂耐药患者，后线治疗的现状如何？随着肿瘤治疗进入精准时代，作为卵巢癌第一个真正意义上的靶向药物PARP抑制剂，后线治疗

姚书忠教授：PARP抑制剂一线维持治疗生物标志物从BRCA+到HRD+，HRD Score检测助力卵巢癌获益人群筛查

随着PARP抑制剂研究的进展，卵巢癌的靶向治疗之路不断扩展。特别是在FDA批准的一线维持治疗中，从奥拉帕利用于BRCA突变人群，到奥拉帕利+贝伐珠单抗用于HRD阳性人群，实现了PARP抑制剂一线维持治

Eur J Cancer：HOXA9 meth-ctDNA可作为BRCA突变卵巢癌的生物标志物

聚(ADP-核糖)聚合酶(PARP)抑制剂已成为BRCA突变卵巢癌(OC)的一种新的治疗选择；然而，反应是可变的，并且缺乏预后和预测性生物标志物。因此，我们研究了循环肿瘤DNA（meth-ctDNA）

ASCO 2020：奥拉帕利用于BRCA-1/2突变铂敏感复发性卵巢癌患者的疗效及安全性分析（SOLO2研究）

在BRCA-1/2突变铂敏感复发性卵巢癌(PSOC)患者中加入奥拉帕利作为维持治疗可显著改善无进展生存期(PFS)，显示出良好的以患者为中心的终点。由于BRCA突变的患者往往更年轻，老年患者使用奥拉帕